These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22718451)

  • 1. [Monoclonal antibodies in nephrology: a delicate balance between curative potential, evidence of effectiveness, and toxicity].
    Magistroni R
    G Ital Nefrol; 2012; 29(3):283-91; discussion 292. PubMed ID: 22718451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of monoclonal antibodies in the treatment of immune-mediated kidney disease: the state of the art].
    Cravedi P
    G Ital Nefrol; 2012; 29(3):274-82; discussion 292. PubMed ID: 22718450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [An innovative approach to the treatment of immune-mediated glomerular diseases].
    Roccatello D
    G Ital Nefrol; 2013; 30(1):. PubMed ID: 23832439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab: emerging treatment strategies of immune-mediated glomerular disease.
    Kattah AG; Fervenza FC
    Expert Rev Clin Immunol; 2012 Jul; 8(5):413-21. PubMed ID: 22882216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of post-transplant glomerulonephritis].
    Sandrini S; Valerio F
    G Ital Nefrol; 2008; 25 Suppl 44():99-106. PubMed ID: 19048593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab treatment in lupus nephritis--where do we stand?
    Gunnarsson I; Jonsdottir T
    Lupus; 2013 Apr; 22(4):381-9. PubMed ID: 23553781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
    Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X
    Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
    Roccatello D; Vangelista A; Pani A
    G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry.
    Terrier B; Launay D; Kaplanski G; Hot A; Larroche C; Cathébras P; Combe B; de Jaureguiberry JP; Meyer O; Schaeverbeke T; Somogyi A; Tricot L; Zénone T; Ravaud P; Gottenberg JE; Mariette X; Cacoub P
    Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1787-95. PubMed ID: 20740617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rationale and clinical evidence for the use of rituximab in glomerular diseases].
    Mani LY; Vogt B; Burnier M; Golshayan D
    Rev Med Suisse; 2011 Apr; 7(290):819-24. PubMed ID: 21595313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature.
    Ferri C; Cacoub P; Mazzaro C; Roccatello D; Scaini P; Sebastiani M; Tavoni A; Zignego AL; De Vita S
    Autoimmun Rev; 2011 Nov; 11(1):48-55. PubMed ID: 21821153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement in psoriasis during rituximab therapy for mixed cryoglobulinemia type II.
    Moberg P; Charles JF; Respicio G; Venna SS; Rooney T
    Cutis; 2010 Sep; 86(3):133-5. PubMed ID: 21049729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases.
    Kattah AG; Fervenza FC; Roccatello D
    Autoimmun Rev; 2013 Jun; 12(8):854-9. PubMed ID: 23000633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Monoclonal antibodies to B-lymphocytes (rituximab) in the treatment of HCV-associated severe cryoglobulinemic glomerulonephritis].
    Milovanova SIu; Lopatkina TN; Kozlovskaia LV; Krasnova TN
    Ter Arkh; 2007; 79(6):69-72. PubMed ID: 17684972
    [No Abstract]   [Full Text] [Related]  

  • 15. Understanding the role of rituximab in ANCA GN: regressing toward the mean.
    Pendergraft WF; Falk RJ
    J Am Soc Nephrol; 2015 Apr; 26(4):771-4. PubMed ID: 25381425
    [No Abstract]   [Full Text] [Related]  

  • 16. Rituximab in immunologic glomerular diseases.
    Ejaz AA; Asmar A; Alsabbagh MM; Ahsan N
    MAbs; 2012; 4(2):198-207. PubMed ID: 22377738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of rituximab in primary and secondary glomerulonephritis].
    Insalaco M; Zanoli L; Fatuzzo P; Fiorini F; Granata A
    G Ital Nefrol; 2015; 32(6):. PubMed ID: 26845209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Belimumab after rituximab as maintenance therapy in lupus nephritis.
    Kraaij T; Huizinga TW; Rabelink TJ; Teng YK
    Rheumatology (Oxford); 2014 Nov; 53(11):2122-4. PubMed ID: 25205827
    [No Abstract]   [Full Text] [Related]  

  • 19. [Rituximab for the treatment of ANCA associated vasculitis: the future today?].
    Alba MA; Flores-Suárez LF
    Reumatol Clin; 2011 Dec; 7 Suppl 3():S41-6. PubMed ID: 22115869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Is rituximab effective for induction of remission in lupus nephritis?].
    Mac-Namara M; Rada G
    Medwave; 2014 Aug; 14(7):e6010. PubMed ID: 25334007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.